Everett E. Vokes to Sulindac
This is a "connection" page, showing publications Everett E. Vokes has written about Sulindac.
Connection Strength
0.041
-
A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. J Thorac Oncol. 2009 Feb; 4(2):220-6.
Score: 0.022
-
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. J Thorac Oncol. 2007 Oct; 2(10):933-8.
Score: 0.020